Cargando…

Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure

Detalles Bibliográficos
Autores principales:	Pieringer, Herwig, Schumacher, Sabine, Schmekal, Bernhard, Gitter, Thomas, Biesenbach, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421164/ https://www.ncbi.nlm.nih.gov/pubmed/25983879 http://dx.doi.org/10.1093/ndtplus/sfn030

Ejemplares similares

An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis
por: Zhang, Bin, et al.
Publicado: (2015)

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
por: Thomsen, Henrik S., et al.
Publicado: (2007)

Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review
por: Lange, Sandra, et al.
Publicado: (2021)

Therapy refractory hypertension in haemodialysis patients has become a rare indication for bilateral nephrectomy
por: Biesenbach, Georg, et al.
Publicado: (2010)

Gadolinium and nephrogenic systemic fibrosis: time to tighten practice
por: Mendichovszky, Iosif A., et al.
Publicado: (2007)

A Case of Delayed Onset Nephrogenic Systemic Fibrosis After Gadolinium Based Contrast Injection
por: Do, Jong Geol, et al.
Publicado: (2012)

Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
por: Leung, Nelson, et al.
Publicado: (2009)

Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager
por: Gallo-Bernal, Sebastian, et al.
Publicado: (2022)

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease
por: Bennett, Charles L., et al.
Publicado: (2012)

Nephrogenic systemic fibrosis
por: Braverman, Irwin M, et al.
Publicado: (2010)

Nephrogenic systemic fibrosis
por: Madke, Bhushan, et al.
Publicado: (2011)

Nephrogenic systemic fibrosis
por: Koratala, Abhilash, et al.
Publicado: (2017)

Complications of nephrogenic systemic fibrosis following repeated exposure to gadolinium in a man with hypothyroidism: a case report
por: Aggarwal, Arpita, et al.
Publicado: (2011)

Gadolinium contrast agents: Over exposure?
por: Biederman, Robert W, et al.
Publicado: (2016)

Understanding Nephrogenic Systemic Fibrosis
por: Chopra, Tushar, et al.
Publicado: (2012)

Gadolinium-DTPA: A New Contrast Agent
por: Niendorf, H. P.
Publicado: (1988)

NEPHROGENIC SYSTEMIC FIBROSIS: TIME FOR THE REQUIEM?
por: Panda, Saumya
Publicado: (2011)

NEPHROGENIC SYSTEMIC FIBROSIS: CURRENT CONCEPTS
por: Basak, Prasanta, et al.
Publicado: (2011)

Nephrogenic Systemic Fibrosis: Mini-Review
por: Mundim, Juliano Sacramento, et al.
Publicado: (2009)

Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats
por: Robert, Philippe, et al.
Publicado: (2016)

Gadolinium Complexes as Contrast Agent for Cellular NMR Spectroscopy
por: Sakol, Nat, et al.
Publicado: (2020)

NEPHROGENIC SYSTEMIC FIBROSIS: A BRIEF REVIEW
por: Waikhom, Rajesh, et al.
Publicado: (2011)

Nephrogenic Systemic Fibrosis Risk and Liver Disease
por: Hanna, Robert F., et al.
Publicado: (2014)

Nephrogenic systemic fibrosis (NSF): the role of tamoxifen
por: Davison, Rachel, et al.
Publicado: (2010)

Nephrogenic systemic fibrosis: A frivolous entity
por: Bhargava, Vinant, et al.
Publicado: (2021)

Fatal anaphylactic reaction to intravenous gadobutrol, a gadolinium-based MRI contrast agent
por: Franckenberg, Sabine, et al.
Publicado: (2017)

Biocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast Agents
por: Jeong, Sang Young, et al.
Publicado: (2010)

Immediate reaction to gadolinium based contrast agent with fatal outcome()()()
por: Behzadi, Ashkan Heshmatzadeh, et al.
Publicado: (2018)

Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series
por: Nucera, Eleonora, et al.
Publicado: (2021)

Gadolinium-based contrast agents in neurofibromatosis type 1 (Review)
por: Năstase, Florentina, et al.
Publicado: (2021)

Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications
por: Fatima, Atiya, et al.
Publicado: (2021)

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review
por: Olchowy, Cyprian, et al.
Publicado: (2017)

Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents
por: Richter, Henning, et al.
Publicado: (2020)

Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T(1) contrast
por: Ananta, Jeyarama S., et al.
Publicado: (2010)

A moderate response to plasmapheresis in nephrogenic systemic fibrosis
por: Ustuner, Pelin, et al.
Publicado: (2011)

Nephrogenic Systemic Fibrosis in Denmark– A Nationwide Investigation
por: Elmholdt, Tina R., et al.
Publicado: (2013)

Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents
por: Ringler, Michael D., et al.
Publicado: (2021)

Gadolinium Retention in the Brain of Mother and Pup Mouse: Effect of Pregnancy and Repeated Administration of Gadolinium‐Based Contrast Agents
por: Yao, Xiang, et al.
Publicado: (2022)

Thermal Excitation of Gadolinium-Based Contrast Agents Using Spin Resonance
por: Dinger, Steven C., et al.
Publicado: (2016)

Acute respiratory distress syndrome after the use of gadolinium contrast agent
por: Kerget, Bugra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pl985b2s8f82d62qa8qk714m11